Colonic Neoplasms

The grounding supports a genetic and molecular basis for at least some colonic neoplasms, including KRAS and BRAF mutation status and deficient DNA mismatch repair or microsatellite instability-high tumors. It also identifies Wnt signaling as a recognized driver of colon cancer and notes gene expression regulation as a studied mechanism, but does not support a single external cause for the disease.

Colon cancer development is linked to dysregulation of the canonical Wnt/β-catenin pathway, with β-catenin modification and degradation described as key events in progression. The literature also implicates tumor microenvironment changes, DNA mismatch repair deficiency, and altered signaling through ERbB-related and RAS/RAF pathways in disease biology.

The supplied grounding supports molecular features associated with treatment selection and disease behavior, including KRAS/NRAS mutations, BRAF mutation status, and microsatellite instability or deficient mismatch repair. It also notes that the location of the primary tumor and patient comorbidities influence management, but does not establish these as causal risk factors for developing the disease.

Treatment is described at the modality and drug-class level as surgery for resectable disease and systemic therapy for advanced disease. Systemic treatment includes fluoropyrimidine-based chemotherapy, oxaliplatin- and irinotecan-containing regimens, trifluridine-based therapy, anti-VEGF antibodies such as bevacizumab, anti-EGFR monoclonal antibodies such as cetuximab and panitumumab in appropriate molecular subsets, and immune checkpoint inhibition such as nivolumab or pembrolizumab for microsatellite instability-high or deficient mismatch repair tumors. Adjuvant chemotherapy is not routinely recommended for medically fit patients with stage II colon cancer based on the cited guideline summary.